| Date Filed | Type | Description |
| 02/14/2013 |
SC 13G/A
| Visium Asset Management, LP reports a 0% stake in Medicis Pharmaceutical Corporation |
| 02/12/2013 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/26/2012 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 12/26/2012 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 12/18/2012 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/11/2012 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 12/11/2012 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement |
| 12/11/2012 |
8-K
| Quarterly results |
| 11/28/2012 |
8-K
| Other Events |
| 11/28/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/21/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 11/21/2012 |
8-K
| Other Events |
| 11/08/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/05/2012 |
8-K
| Other Events |
| 11/05/2012 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 11/01/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 10/17/2012 |
8-K
| Other Events |
| 10/17/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 10/09/2012 |
8-K
| Other Events |
| 09/25/2012 |
8-K
| Other Events |
| 09/21/2012 |
GN
| Medicis Declares Cash Dividend |
| 09/06/2012 |
PRN
| Levi & Korsinsky, LLP Announces Investigation of Medicis Pharmaceutical Corporation (MRX), FSI Internaltional Inc. (FSII) and Deltek, Inc. (PROJ) |
| 09/04/2012 |
PRN
| Law Office of Brodsky & Smith, LLC Announces Investigation of Medicis Pharmaceutical Corporation |
| 09/04/2012 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger, among Medicis Pharmaceutical Corporation, Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc. and Merlin Merger Sub, Inc",
"Settlement Agreement, between Medicis Pharmaceutical Corporation and Deutsche Bank AG, London Branch",
"VALEANT PHARMACEUTICALS INTERNATIONAL, INC. AGREES TO ACQUIRE MEDICIS PHARMACEUTICAL CORPORATION FOR $44.00 PER SHARE IN CASH Combination Creates a Global Leader in Dermatology Transaction Values Medicis at Approximately $2.6 Billion At Least $225 Million Run Rate in Annual Cost Synergies Expected to be Achieved within 6 Months of Closing Transaction Expected to Close in the First Half of 2013",
"Medicis Pharmaceutical Corporation communications" |
|
| 09/04/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 09/04/2012 |
PRN
| Harwood Feffer LLP Announces Investigation of Medicis Pharmaceutical Corp. |
| 09/03/2012 |
PRN
| Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash |
|